Abstract
The management of well-differentiated thyroid cancer requires endogenous or exogenous thyrotropin (TSH) stimulation for diagnostic and therapeutic purposes. The rationale is to increase the sensitivity of follow-up tests and to optimize the radioiodine uptake, respectively. Withdrawal of L-thyroxine therapy in order to provoke endogenous stimulation and elevation of TSH is associated with symptomatic hypothyroidism that significantly affects quality of life. More importantly, because TSH stimulates growth of thyroid cells, prolonged TSH elevation may worsen the thyroid cancer, and the profound hypothyroidism may aggravate other underlying systemic diseases.
As an alternative to thyroxine withdrawal, exogenous stimulation consists of two intramuscular injections of recombinant human thyrotropin α (rhTSH). This procedure is effective in terms of sufficient TSH stimulation and obviates development in the patient of the signs and symptoms of hypothyroidism. Taking into consideration the increased incidence of thyroid cancer, as well as the necessity for life-long follow-up, the optimal management of the disease must meet goals for efficacy, safety, quality of life and optimal cost/benefit ratio.
This article reviews current standard procedures and potential novel clinical applications of rhTSH for the management of well-differentiated thyroid cancer.
Keywords: rhTSH, Thyroid cancer, Remnant Ablation, Metastases, Follow-up
Current Pharmaceutical Analysis
Title: Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review
Volume: 6 Issue: 1
Author(s): Joanna Klubo-Gwiezdzinska, Kenneth D. Burman, Douglas Van Nostrand and Leonard Wartofsky
Affiliation:
Keywords: rhTSH, Thyroid cancer, Remnant Ablation, Metastases, Follow-up
Abstract: The management of well-differentiated thyroid cancer requires endogenous or exogenous thyrotropin (TSH) stimulation for diagnostic and therapeutic purposes. The rationale is to increase the sensitivity of follow-up tests and to optimize the radioiodine uptake, respectively. Withdrawal of L-thyroxine therapy in order to provoke endogenous stimulation and elevation of TSH is associated with symptomatic hypothyroidism that significantly affects quality of life. More importantly, because TSH stimulates growth of thyroid cells, prolonged TSH elevation may worsen the thyroid cancer, and the profound hypothyroidism may aggravate other underlying systemic diseases.
As an alternative to thyroxine withdrawal, exogenous stimulation consists of two intramuscular injections of recombinant human thyrotropin α (rhTSH). This procedure is effective in terms of sufficient TSH stimulation and obviates development in the patient of the signs and symptoms of hypothyroidism. Taking into consideration the increased incidence of thyroid cancer, as well as the necessity for life-long follow-up, the optimal management of the disease must meet goals for efficacy, safety, quality of life and optimal cost/benefit ratio.
This article reviews current standard procedures and potential novel clinical applications of rhTSH for the management of well-differentiated thyroid cancer.
Export Options
About this article
Cite this article as:
Klubo-Gwiezdzinska Joanna, Burman D. Kenneth, Nostrand Van Douglas and Wartofsky Leonard, Diagnostic and Therapeutic Use of Human Recombinant Thyrotropin (rhTSH)(Thyrogen®) in Well-Differentiated Thyroid Cancer - Current Indications and Future Perspectives - A Review, Current Pharmaceutical Analysis 2010; 6 (1) . https://dx.doi.org/10.2174/157341210790780203
DOI https://dx.doi.org/10.2174/157341210790780203 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Gold Nanoparticle Based Systems in Genetics
Current Pharmacogenomics Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design Recent Progresses in Identifying Nuclear Receptors and Their Families
Current Topics in Medicinal Chemistry The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Relationship Between Vitamin D Deficiency and Chronic Low Back Pain in Postmenopausal Women
Current Rheumatology Reviews Measurement of Entrance Skin Dose in Radiographic Examinations of Pediatric Patients
Current Medical Imaging Multiscale Modelling of Relationships between Protein Classes and Drug Behavior Across all Diseases Using the CANDO Platform
Mini-Reviews in Medicinal Chemistry Biodistribution and Pharmacokinetics of PEG-10kDa-Cholecystokinin-10 in Rats After Different Routes of Administration
Current Drug Delivery The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
Current Topics in Medicinal Chemistry Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study
Current HIV Research Anticancer Activity of Ocimum basilicum and the Effect of Ursolic Acid on the Cytoskeleton of MCF-7 Human Breast Cancer Cells
Letters in Drug Design & Discovery Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Microtubules in Apoptosis Induction: Are They Necessary?
Current Cancer Drug Targets L-Sulforaphane Confers Protection Against Oxidative Stress in an In Vitro Model of Age-Related Macular Degeneration
Current Molecular Pharmacology Current and Future Trends in Early Detection of Pancreatic Cancer: Molecular Targets and PET Probes
Current Medicinal Chemistry